Learning from a clinical cohort for HCV vaccine development

About 71 million people worldwide suffer from chronic hepatitis C virus (HCV) infection. Without available treatment the large majority of HCV-infected patients progress to chronic disease. Chronic HCV infection is one of the most important risk factors for liver disease, including liver fibrosis, cirrhosis and hepatocellular carcinoma. Despite the development of efficient direct-acting antivirals with success rates of more than 95%, HCV incidence rates are still increasing, which is in part due to the ongoing opioid epidemic that is currently taking its toll in the US.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research